Integrated Hepatitis Testing: What's new in Viral Hepatitis Diagnosis and Management?

Description

This session highlights the laboratory’s essential role in addressing the global burden of hepatitis B and C. Attendees will examine current epidemiological trends, key diagnostic challenges, and evidence-based testing strategies. The session will emphasize integrated testing algorithms and advanced virological tools that support early detection, accurate diagnosis, and effective disease management across both developed settings and high-risk or underserved populations.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, pathologists, residents, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Analyze global and regional epidemiological trends of hepatitis B and C, and evaluate their impact on public health systems and disease elimination efforts. 
• Identify and apply appropriate immunoassay and molecular testing for hepatitis screening, diagnosis, and monitoring.
• Interpret and apply integrated testing algorithms with a focus on high-risk populations and alignment with current clinical guidelines.

Faculty

Stephane Chevaliez, PharmD-Ph.D
Department of Virology, French National Reference Center for Hepatitis B, C and D Viruses, Hôpital Henri Mondor (AP-HP)
Université Paris-Est, Créteil, France; Team “Viruses, Hepatology, Cancer“, Institut de Recherche Biomédicale, INSERM U955
Créteil, France

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Stephane Chevaliez, PharmD-Ph.D
  • Honorarium/Expenses: Gilead Sciences
  • Consulting Fees: Roche and Abbvie

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity will be submitted for 1.0 ACCENT continuing education credit.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].